SpyGlass DS Template Press Release (continued)Page 1 of 2
[City, State], [Date], 2015 – [Name of physician] [M.D. / D.O.],[title] with[name of institution or practice] is using newminimally invasive technologyto help diagnose and treat diseases and conditions in the bile duct, hepatic ducts, and pancreas. This advancedtechnology, the SpyGlass™ DS Direct Visualization System,enables high resolution imaging and therapy during an ERCP procedureto target biopsies and fragment stones. This may result in more efficient evaluation and help reduce the need for additional testing and repeat procedurescompared with standard cytology brushing and standard forceps biopsy1, enablingpatients to receive treatment sooner.
An estimated 500,000individuals undergo endoscopic retrograde cholangiopancreatography (ERCP) procedures each year in the U.S. for liver, gallbladder, pancreas and bile duct problems1.During an ERCP procedure, the SpyGlass DS System may be used to help investigate, confirm and treat conditions such as gallstones, suspected malignancies (such as pancreatic cancer), bile duct strictures and cystic lesions.
Boston Scientific, a medical device company headquartered in Marlborough, MA, launched the original SpyGlass System in 2007 as the first single operator cholangioscopy device. The SpyGlass System representeda significant breakthrough in cholangioscopy technology and has since been used in more than 50,000 procedures worldwide with over 125 articles published or presented on its clinical utility. The new next generation SpyGlass DS System builds on its legacy technology by providing physicians with enhanced visualization and an easier ‘plug and play’ set-up to improve procedural efficiency.
“The SpyGlass™ DS System is changing the way I approach patient management,” explained Dr. [Name]. “It enables me to both diagnose and treat the symptoms of difficult pancreatico-biliary disease during one procedure.In many cases, my patients suffer from serious conditions and using this technology helps me make an earlier diagnosis,provide faster relief of their symptoms, and may reduce the need for repeat procedures.”
The SpyGlass DS Direct Visualization System, developed by Boston Scientific, received 510(k) clearance in the U.S. by the Food and Drug Administration (FDA) in January 2015.
Physician Information:
[Name, M.D. / D.O.] is board-certified and has been a practicing gastroenterologist for the past [number of years] years in [City]. [He/She] received [his/her] training at [Institution] currently practices at [Institution Name]. [He/She] has continued to perform many advanced procedures and has been influential in advances in gastroenterology.
# # #